The San Clemente, Calif.-based company reported profits of $18.9 million, or 88¢ per share, on sales of $303.4 million for the three months ended June 30, for a bottom-line loss of -17.2% sales loss of -2.8% compared with Q2 2019.
Earnings per share were 88¢, 14¢ ahead of The Street, where analysts were looking for sales of $283.4 million.
“Second quarter results were generally in line with our expectations and reflected strong demand for our infusion pumps due to the COVID-19 pandemic,” CEO Vivek Jain said in a news release.
ICU Medical did not provide a financial outlook for the rest of its fiscal year.
Shares in ICUI were up 6.22% to $190 apiece in pre-market hours.